Avidity Biosciences - RNA Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" RNA shares.
View RNA analyst ratings or view top-rated stocks.

6 analysts have issued 12 month target prices for Avidity Biosciences' stock. Their RNA share price forecasts range from $27.00 to $59.00. On average, they predict the company's stock price to reach $39.50 in the next twelve months. This suggests a possible upside of 242.0% from the stock's current price.
View analysts price targets for RNA or view top-rated stocks among Wall Street analysts.

Avidity Biosciences' stock was trading at $23.77 at the beginning of the year. Since then, RNA stock has decreased by 51.4% and is now trading at $11.55.
View the best growth stocks for 2022 here.

Avidity Biosciences saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 7,030,000 shares, an increase of 26.7% from the October 31st total of 5,550,000 shares. Based on an average trading volume of 533,200 shares, the short-interest ratio is presently 13.2 days.
View Avidity Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our RNA earnings forecast.

Avidity Biosciences, Inc. (NASDAQ:RNA) announced its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.68). The biotechnology company had revenue of $2.16 million for the quarter, compared to analyst estimates of $1.50 million. Avidity Biosciences had a negative net margin of 1,950.91% and a negative trailing twelve-month return on equity of 42.97%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

(RNA) raised $150 million in an initial public offering on Friday, June 12th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO.

Avidity Biosciences trades on the NASDAQ under the ticker symbol "RNA."

Avidity Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.49%), Price T Rowe Associates Inc. MD (9.49%), BlackRock Inc. (7.57%), EcoR1 Capital LLC (5.32%), Vanguard Group Inc. (4.95%) and Federated Hermes Inc. (4.55%). Insiders that own company stock include Arthur A Levin, Rtw Investments, Lp and Sarah Boyce.
View institutional ownership trends.

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RNA stock can currently be purchased for approximately $11.55.

Avidity Biosciences (NASDAQ:RNA) has a market capitalization of $629.01 million and generates $9.33 million in revenue each year. The biotechnology company earns $-118,010,000.00 in net income (profit) each year or ($3.27) on an earnings per share basis.

The company employs 125 workers across the globe.

Avidity Biosciences' mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The official website for the company is www.aviditybiosciences.com. The biotechnology company can be reached via phone at 858-401-7900 or via email at amy@juniper-point.com.